FocalTherics (FOCL) has reaffirmed its 2026 revenue outlook for its High-Intensity Focused Ultrasound (HIFU) technology, projecting figures between $50 million and $54 million. This reiteration arrives as the company successfully closed a $40 million equity offering, significantly bolstering its financial position and strategic capabilities.
The successful completion of the $40 million equity offering is a key financial milestone for FocalTherics. CEO and Director Ryan Rhodes articulated the profound significance of this period, describing it as “a transformative moment in the evolution of our company’s history.” This transformation includes the strategic rebranding from EDAP to FocalTherics, a move designed to underscore its identity as a “pure-play, high-growth, market-leading focal therapy company.” The capital infusion is expected to support this focused strategic direction.
The consistent reaffirmation of the 2026 HIFU revenue guidance, first outlined during the Q2 2026 management view, reflects the company’s robust confidence in the market’s reception and the growth trajectory of its specialized focal therapy solutions. This financial outlook, coupled with the fresh capital, positions FocalTherics to invest further in its core technologies and market penetration efforts.
With a clear financial runway provided by the equity offering and a steadfast commitment to its ambitious revenue targets, FocalTherics is strategically advancing its mission to establish a dominant presence in the rapidly evolving focal therapy sector.
